Cancer clinical trials are our most powerful weapon in being able to identify better ways to treat breast cancer, better ways to detect breast cancer and better ways to prevent breast cancer. As we continue to learn more about the heterogeneity, the diversity of the breast cancer disease, we have to understand more about the nature of breast cancer as it afflicts women of different racial-ethnic backgrounds.
As we catalog, as we understand the genetics of this disease in diverse patient populations, we will have a much better global understanding of this disease and better ways to treat the disease. Being able to comprehensively evaluate that disease means that we need to have diverse patients involved in our research and involved in our clinical trials.
We have to be able to be sure that the treatments available are appropriate for women with all different characteristics; including racial-ethnic identities.